Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Staar Surgical to $33 from $40 and keeps a Neutral rating on the shares. The firm notes Staar reported full Q4 results that were in-line with the January preannouncement on the top-line and ahead on the bottom line. Management reiterated its 2024 revenue outlook, which calls for modest growth. The company is probably being a bit conservative, but Piper does see challenges ahead in its main growth markets.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on STAA:
- Is STAA a Buy, Before Earnings?
- Staar Surgical announces strategic pact in U.S. with SharpeVision, no terms
- Staar Surgical price target lowered to $31 from $33 at Canaccord
- Fly Insider: Athira Pharma, Microstrategy among week’s notable insider trades
- Staar Surgical sees FY24 revenue $335M -$340M, consensus $366.8M
